文献速递特殊人群用药药物不良反应与药物警戒

呼吁行动:上市后妊娠与哺乳期安全性研究的药物警戒法规协调

Call to action: Harmonization of pharmacovigilance regulations for post-marketing pregnancy and breastfeeding safety studies.
PubMed 文献 · Br J Clin Pharmacol · 2023-11-15

全球每年逾2亿女性妊娠,多数用药但妊娠期安全数据有限,源于该人群常规被排除于临床试验。TransCelerate IGR PV妊娠与哺乳团队综述全球法规,发现多数地区缺乏针对上市后妊娠与哺乳安全性研究的明确法规且缺乏协调,亦无ICH标准指导此类研究。

要点

  • 多数地区缺乏上市后妊娠与哺乳安全性研究的明确法规或指南
  • 目前无ICH标准指导此类上市后安全性研究
  • 法规协调可促进研究及时完成并优化妊娠用药获益风险决策

核心结论

  • 全球上市后妊娠与哺乳安全性研究法规缺乏协调,多数地区无明确法规或指南,亦无ICH标准指导。

研究设计与样本

  • TransCelerate IGR PV妊娠与哺乳团队对全球妊娠与哺乳用药法规指南进行综述,以ICH标准与CIOMS指南为基准。

主要发现

  • 评估发现全球妊娠与哺乳女性研究法规缺乏协调,多数评估地区缺乏该主题的具体法规。
  • 目前无ICH标准指导上市后妊娠与哺乳安全性研究,多数地区无明确法规或指南说明何时及如何开展。

临床怎么用

  • 临床药学智能体应关注妊娠与哺乳期用药上市后安全性证据的获取与解读。
  • 在缺乏协调法规背景下,需依赖上市后数据评估妊娠与哺乳期用药获益风险。

局限性

  • 原文为呼吁性文章,未报告系统检索策略、纳入地区数量或具体法规条款细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Globally, more than 200 million women become pregnant each year, most of whom receive medications despite limited information on their safe use during pregnancy. The paucity of drug safety data on pregnant and breastfeeding women stems from the routine exclusion of this population from clinical trials due to scientific, ethical, regulatory and legal concerns. Consequently, at the time of initial drug approval, there may be scant safety data to inform the drug benefit-risk balance to the mother, foetus or infant. Although momentum is growing to include this underrepresented population in clinical trials, most information on drug exposure outcomes comes from data collected in the postmarketing setting. Regulatory guidance and legislation on medication use in pregnancy and breastfeeding were reviewed globally by the TransCelerate IGR PV Pregnancy and Breastfeeding Team. The International Conference of Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) standards and Council for International Organizations of Medical Sciences guidelines served as benchmarks for national safety regulations and guidance. The landscape assessment identified a lack of harmonization of global regulations on research in pregnant and breastfeeding women and a lack of specific regulations on this topic in the majority of the territories included in the assessment. This article focuses on the ambiguities and lack of harmonization in global regulations on postmarketing pregnancy and breastfeeding safety studies. There is currently no ICH standard to guide these types of safety studies and, in most regions reviewed, there are no clear regulations or guidance on when and how to conduct them. While a challenging undertaking, greater clarity and harmonization would facilitate more timely completion of postmarketing pregnancy safety studies that would ultimately generate the critical data needed to optimize benefit-risk decisions for women who may conceive, as well as pregnant and breastfeeding women.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Alexe A, Eisele O, Fernandes MFS, et al. Call to action: Harmonization of pharmacovigilance regulations for post-marketing pregnancy and breastfeeding safety studies. Br J Clin Pharmacol. 2023. PMID: 37793773. doi:10.1111/bcp.15920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。